ClinicalTrials.gg
TerminatedNCT01287741Updated Apr 12, 2019Results posted

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

A Phase 3 interventional study of Rituximab and Obinutuzumab in Diffuse Large B-Cell Lymphoma, sponsored by Hoffmann-La Roche. Terminated at 235 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-12.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
The study was closed by the Sponsor according to the protocol-specified minimum post-treatment follow-up period of 3 years.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,418
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse — 4 open to participants now, 6 under way, none of them phase 3. obinutuzumab · Lymphoma, Large B-Cell, Diffuse.

Enrollment
Largest of 17
1,418 · median 48
Started
2011
the only one that year
Phase 3
Only one
of the 17
Registered
1st of 17
by date
Lead sponsor
3 of 17
Hoffmann-La Roche

Among the 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 3, and was the 1st registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

4 of the 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About obinutuzumab

obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m\^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously untreated CD20-positive DLBCL
  • At least 1 bi-dimensionally (greater than [>]1.5 centimeters [cm] in its largest dimension on the computed tomography [CT] scan)
  • (ECOG) performance status 0, 1 or 2
  • Adequate hematological function
  • Low-intermediate, high-intermediate or high-risk International Prognostic Index (IPI) score (low-risk IPI score: IPI 1 irrespective of bulky disease or IPI 0 with bulky disease, defined as one lesion greater than equal to (>/=) 7.5 cm)
  • (LVEF) >/=50 percent (%) on cardiac multiple-gated acquisition (MUGA) scan or cardiac echocardiogram

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products or to any component of CHOP or obinutuzumab
  • to any of the individual components of CHOP, including prior receipt of anthracyclines
  • Participants with transformed lymphoma and participants with follicular lymphoma IIIB
  • Prior therapy for DLBCL, with the exception of nodal or local irradiation
  • Prior treatment with cytotoxic drugs or rituximab for another condition (for example, rheumatoid arthritis) or prior use of an anti-CD20 antibody
  • Prior use of any monoclonal antibody within 3 months of the start of Cycle 1
  • use of >30 milligrams per day (mg/day) of prednisone or equivalent, for purposes other than lymphoma symptom control
  • Primary central nervous system (CNS) lymphoma and secondary CNS involvement by lymphoma, mantle-cell lymphoma (MCL), or histologic evidence of transformation to a Burkitt lymphoma, primary mediastinal DLBCL, primary effusion lymphoma, plasmablastic lymphoma, and primary cutaneous DLBCL
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,418 participants (actual)

Study arms

  • Active comparator
    Rituximab+Chemotherapy

    Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

  • Experimental
    Obinutuzumab+Chemotherapy

    Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.

    Drug: Obinutuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone

Interventions

  • Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.

    Also known as: MabThera, Rituxan

  • Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.

    Also known as: GA101, RO5072759

  • Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.

  • Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.

  • Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.

  • Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Median Time to Progression-Free Survival (PFS), Investigator-Assessed

    Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).

    Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)

Secondary outcomes

  1. Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed

    Kaplan Meier estimate of median PFS was defined as time at which half of participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as time from randomization until first documented day of disease progression or relapse, using a modified version of Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT or MRI. This outcome measure used data from primary analysis which included all 1418 participants.

    Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)

  2. Median Time to Overall Survival (OS)

    Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)

  3. Overall Response Rate (ORR), Investigator-Assessed

    Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.

    Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)

  4. Overall Response Rate (ORR), IRC-Assessed

    Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. This outcome measure used data from primary analysis which included all 1418 participants.

    Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)

  5. Complete Response (CR) at the End of Treatment, Investigator-Assessed

    Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.

    Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)

  6. Complete Response (CR) at the End of Treatment, IRC-Assessed

    Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. This outcome measure used data from primary analysis which included all 1418 participants.

    Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)

  7. Median Time to Event-Free Survival (EFS), Investigator-Assessed

    Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed. Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.

    Time frame: Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, approximately 6.5 years (up to 31 January 2018)

  8. Median Time to Disease-Free Survival (DFS), Investigator-Assessed

    Kaplan Meier estimate of median DFS was defined as time at which half of participants have disease progression/relapse or death from any cause. Disease-free survival was defined as time from date of the first occurrence of a documented CR to date of disease progression/relapse or death from any cause on basis of investigator assessments with use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.

    Time frame: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)

  9. Duration of Response (DOR), Investigator-Assessed

    DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression \>/= 50%. Progression/relapse: at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.

    Time frame: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)

  10. Time to Next Anti-Lymphoma Treatment (TTNALT)

    Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.

    Time frame: Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, approximately 6.5 years (31 January 2018)

  11. Percentage of Participants With Adverse Events (AEs)

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)

  12. Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab

    The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.

    Time frame: Pre-dose (Hour 0) on Cycle (C) 4 Day (D) 1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)

  13. Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score

    The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.

    Time frame: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)

  14. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores

    The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.

    Time frame: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)

  15. Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

    Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.

    Time frame: C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)

07

Results

Posted Aug 17, 2017

Participant flow

Participant flow — Overall Study
MilestoneRituximab+ChemotherapyObinutuzumab+Chemotherapy
Started712706
Completed8691
Not completed626615
Withdrew: Withdrawal by subject3538
Withdrew: Protocol violation20
Withdrew: Physician decision1523
Withdrew: Non-compliance86
Withdrew: Lost to follow-up108
Withdrew: Death3244
Withdrew: Adverse event46
Withdrew: Study terminated by sponsor307315
Withdrew: Progressive disease190166
Withdrew: Reason not specified239

Outcome measures

PrimaryMedian Time to Progression-Free Survival (PFS), Investigator-Assessed

Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).

Time frame:
Baseline up to approximately 6.5 years (up to 31 January 2018)
Reported as:
Median · months
Median Time to Progression-Free Survival (PFS), Investigator-Assessed
monthsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Median Time to Progression-Free Survival (PFS), Investigator-Assessed74.5 (NA to NA)68.3 (68.3 to NA)
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.4753 · Hazard ratio (hr): 0.94 · 95% CI 0.78 to 1.12Stratified by International Prognostic Index (IPI) score (low/low-intermediate (excluding participants having an IPI score 0 without bulky disease).
SecondaryMedian Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed

Kaplan Meier estimate of median PFS was defined as time at which half of participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as time from randomization until first documented day of disease progression or relapse, using a modified version of Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT or MRI. This outcome measure used data from primary analysis which included all 1418 participants.

Time frame:
Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Reported as:
Median · months
Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed
monthsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-AssessedNA (NA to NA)NA (NA to NA)
Statistical analysis
  • Rituximab+Chemotherapy vs Obinutuzumab+Chemotherapy · Log Rank · p = 0.2736 · Hazard ratio (hr): 0.89 · 95% CI 0.72 to 1.10Stratified by International Prognostic Index (IPI) score (low/low-intermediate (excluding participants having an IPI score 0 without bulky disease).
SecondaryMedian Time to Overall Survival (OS)

Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause.

Time frame:
Baseline up to approximately 6.5 years (up to 31 January 2018)
Reported as:
Median · months
Median Time to Overall Survival (OS)
monthsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Median Time to Overall Survival (OS)NA (NA to NA)NA (NA to NA)
SecondaryOverall Response Rate (ORR), Investigator-Assessed

Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.

Time frame:
Baseline up to approximately 6.5 years (up to 31 January 2018)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR), Investigator-Assessed
percentage of participantsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET80.181.4
With PET77.677.1
SecondaryOverall Response Rate (ORR), IRC-Assessed

Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. This outcome measure used data from primary analysis which included all 1418 participants.

Time frame:
Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Reported as:
Number · percentage of participants
Overall Response Rate (ORR), IRC-Assessed
percentage of participantsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET80.282.3
With PET81.182.1
SecondaryComplete Response (CR) at the End of Treatment, Investigator-Assessed

Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.

Time frame:
Baseline up to approximately 6.5 years (up to 31 January 2018)
Reported as:
Number · percentage of participants
Complete Response (CR) at the End of Treatment, Investigator-Assessed
percentage of participantsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET33.935.4
With PET59.156.5
SecondaryComplete Response (CR) at the End of Treatment, IRC-Assessed

Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. This outcome measure used data from primary analysis which included all 1418 participants.

Time frame:
Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Reported as:
Number · percentage of participants
Complete Response (CR) at the End of Treatment, IRC-Assessed
percentage of participantsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Without PET34.439.1
With PET65.366.7
SecondaryMedian Time to Event-Free Survival (EFS), Investigator-Assessed

Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed. Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.

Time frame:
Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Reported as:
Mean · months
Median Time to Event-Free Survival (EFS), Investigator-Assessed
monthsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Median Time to Event-Free Survival (EFS), Investigator-Assessed74.5 (NA to NA)68.3 (68.3 to NA)
SecondaryMedian Time to Disease-Free Survival (DFS), Investigator-Assessed

Kaplan Meier estimate of median DFS was defined as time at which half of participants have disease progression/relapse or death from any cause. Disease-free survival was defined as time from date of the first occurrence of a documented CR to date of disease progression/relapse or death from any cause on basis of investigator assessments with use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.

Time frame:
Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Reported as:
Median · months
Median Time to Disease-Free Survival (DFS), Investigator-Assessed
monthsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Median Time to Disease-Free Survival (DFS), Investigator-AssessedNA (NA to NA)65.4 (NA to NA)
SecondaryDuration of Response (DOR), Investigator-Assessed

DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression \>/= 50%. Progression/relapse: at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.

Time frame:
Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Reported as:
Median · months
Duration of Response (DOR), Investigator-Assessed
monthsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Duration of Response (DOR), Investigator-Assessed71.9 (NA to NA)NA (65.4 to NA)
SecondaryTime to Next Anti-Lymphoma Treatment (TTNALT)

Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.

Time frame:
Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, approximately 6.5 years (31 January 2018)
Reported as:
Median · months
Time to Next Anti-Lymphoma Treatment (TTNALT)
monthsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Time to Next Anti-Lymphoma Treatment (TTNALT)NA (74.5 to NA)NA (NA to NA)
SecondaryPercentage of Participants With Adverse Events (AEs)

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline up to approximately 6.5 years (up to 31 January 2018)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsRituximab+ChemotherapyObinutuzumab+Chemotherapy
Percentage of Participants With Adverse Events (AEs)95.398.1
SecondaryPercentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab

The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.

Time frame:
Pre-dose (Hour 0) on Cycle (C) 4 Day (D) 1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab
percentage of participantsObinutuzumab+Chemotherapy
Screening2.0
Cycle 4 Day 10
Study Completion / Early Discontinuation0
Follow-Up Month 60
Follow-Up Month 120
Follow-Up Month 180
Follow-Up Month 240
Follow-Up Month 300
Follow-Up Completion/ Early Discontinuation0
Unscheduled0
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score

The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.

Time frame:
Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score
score on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Baseline45.34 ± 10.1645.18 ± 9.86
Score Change, Cycle 3 Day 13.83 ± 8.653.70 ± 9.13
Score Change, Study Compl./Discont.5.03 ± 10.214.35 ± 11.03
Score Change, Follow-Up Month 126.37 ± 10.126.18 ± 10.51
Score Change, Follow-Up Month 247.07 ± 10.356.66 ± 10.50
Score Change, Follow-Up Month 30—25.00 ± NA
Score Change, Follow-Up Month 367.57 ± 10.167.31 ± 10.67
Score Change, Follow-Up Month 488.22 ± 9.657.37 ± 10.45
Score Change, Follow-Up Term./Compl.5.51 ± 10.045.55 ± 10.62
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores

The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.

Time frame:
Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores
score on a scaleRituximab+ChemotherapyObinutuzumab+Chemotherapy
Baseline59.81 ± 24.3958.55 ± 25.23
Change Baseline, Cycle 3 Day 16.37 ± 23.777.51 ± 25.99
Change Baseline, Study Completion9.84 ± 25.9610.22 ± 30.17
Change Baseline, Follow-Up Month 1212.67 ± 26.3113.84 ± 29.97
Change Baseline, Follow-Up Month 2414.74 ± 26.3315.81 ± 29.24
Change Baseline, Follow-Up Month 30—58.33 ± NA
Change Baseline, Follow-Up Month 3615.01 ± 26.8517.99 ± 28.85
Change Baseline, Follow-Up Month 4816.62 ± 27.4917.53 ± 30.31
Change Baseline, Follow-Up Completion8.74 ± 29.408.46 ± 28.71
SecondarySerum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.

Time frame:
C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
micrograms per milliliter (μg/mL)Obinutuzumab+Chemotherapy
Cycle 1, Day 8 pre-infusion174 ± 38.7
Cycle 1, Day 15 pre-infusion320 ± 39.2
Cycle 2, Day 1 pre-infusion431 ± 39.8
Cycle 4, Day 1 pre-infusion352 ± 42.1
Cycle 6, Day 1 pre-infusion378 ± 45.9
Cycle 8, Day 1 pre-infusion478 ± 43.9
Cycle 1, Day 1 post-infusion435 ± 32.3
Cycle 1, Day 1 20-28 hours after end of infusion259 ± 56.3
Cycle 1, Day 1 66-80 hours after end of infusion219 ± 51.2
Cycle 1, Day 8 post-infusion578 ± 37.8
Cycle 1, Day 15 post-infusion718 ± 32.9
Cycle 2, Day 1 post-infusion938 ± 31.3
Cycle 4, Day 1 post-infusion817 ± 28.6
Cycle 6, Day 1 post-infusion813 ± 32.6
Cycle 8, Day 1 post-infusion881 ± 35.9

Adverse events

Collected over 6 years and 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab+Chemotherapy—269/701 (38.4%)613/701 (87.4%)
Obinutuzumab+Chemotherapy—312/702 (44.4%)646/702 (92%)
Most frequent serious events
Showing 10 of 325
Most frequent serious events
EventRituximab+ChemotherapyObinutuzumab+Chemotherapy
Febrile neutropeniaBlood and lymphatic system disorders71/70185/702
NeutropeniaBlood and lymphatic system disorders38/70154/702
PneumoniaInfections and infestations33/70143/702
PyrexiaGeneral disorders11/70117/702
SepsisInfections and infestations10/70116/702
LeukopeniaBlood and lymphatic system disorders6/70114/702
ThrombocytopeniaBlood and lymphatic system disorders2/70112/702
Septic shockInfections and infestations3/70112/702
AnaemiaBlood and lymphatic system disorders6/7019/702
Atrial fibrillationCardiac disorders4/7019/702
Most frequent other events
Showing 10 of 39
Most frequent other events
EventRituximab+ChemotherapyObinutuzumab+Chemotherapy
NeutropeniaBlood and lymphatic system disorders269/701315/702
Infusion related reactionInjury, poisoning and procedural complications162/701251/702
NauseaGastrointestinal disorders199/701210/702
ConstipationGastrointestinal disorders177/701167/702
AlopeciaSkin and subcutaneous tissue disorders144/701148/702
PyrexiaGeneral disorders75/701137/702
FatigueGeneral disorders124/701136/702
ChillsGeneral disorders37/701132/702
LeukopeniaBlood and lymphatic system disorders90/701117/702
DiarrhoeaGastrointestinal disorders91/701113/702

Baseline characteristics

The intent-to-treat (ITT) population included all randomized participants. However, 4 patients were classified as misconduct patients and were not included in the ITT population.

Age, Continuous
Age, Continuous(years)Rituximab+ChemotherapyObinutuzumab+ChemotherapyTotal
Mean59.1 ± 13.659.4 ± 13.359.2 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab+ChemotherapyObinutuzumab+ChemotherapyTotal
Female328336664
Male382368750
08

Study locations

235 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294-3300, United States
  • Ironwood Cancer TX & Rsch Ctrs
    Chandler, Arizona 85224, United States
  • Arizona Oncology
    Tucson, Arizona 85704, United States
  • California Cancer Associates for Research & Excellence, Inc.
    Encinitas, California 92008, United States
  • cCare
    Encinitas, California 92024, United States
  • UCLA - School of Medicine; Division of Hematology/Oncology
    Los Angeles, California 90095-6984, United States
  • Rocky Mountain Cancer Center - Aurora
    Aurora, Colorado 80012, United States
  • Florida Cancer Specialists; Department of Oncology
    Fort Myers, Florida 33901-8101, United States
  • Florida Cancer Specialists; Saint Petersburg
    Saint Petersburg, Florida 33719, United States
  • Central Georgia Cancer Care PC
    Macon, Georgia 31201, United States
  • Illinois Cancer Care, P.C. - Galesburg
    Galesburg, Illinois 61401, United States
  • Joliet Oncology-Hematology; Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Cancer Care & Hematology; Specialists of Chicagoland
    Niles, Illinois 60714, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Mercy Oncology / Hematology Center; Oncology
    Portland, Maine 04102, United States
  • Park Nicollet Clin-Cancer Ctr
    Saint Louis Park, Minnesota 55426, United States
  • Minnesota Oncology Hematology Woodbury
    Woodbury, Minnesota 55125, United States
  • New York Oncology Hematology, P.C.
    Albany, New York 12206, United States
  • Mecklenburg Medical Group Charlotte
    Charlotte, North Carolina 28204, United States
  • Forsyth Regional Cancer Center; Piedmont Hematology/Oncology Associates
    Winston-Salem, North Carolina 27103, United States
  • Signal Point Clinical; Research Center, LLC
    Middletown, Ohio 45042, United States
  • Cleveland CL N Coast Cancer Cr
    Sandusky, Ohio 44870, United States
  • Willamette Valley Cancer Insitute and Research Center
    Springfield, Oregon 97477, United States
  • Medical University of SC (MUSC)
    Charleston, South Carolina 29425, United States
  • South Carolina Oncology Associates - SCRI
    Columbia, South Carolina 29210, United States
  • Chattanooga Oncology and Hematology Associates, PC
    Chattanooga, Tennessee 37404, United States
  • Tennessee Onc., PLLC - SCRI
    Nashville, Tennessee 37203, United States
  • Texas Oncology, Pa - Amarillo
    Amarillo, Texas 79106, United States
  • Texas Oncology-Fort Worth 12th Ave
    Fort Worth, Texas 76104, United States
  • MD Anderson Cancer Center Department of Lymphoma & Myeloma
    Houston, Texas 77030, United States
  • Cancer Care Centers of South Texas-HOAST - San Antonio
    New Braunfels, Texas 78130, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23226, United States
  • Blue Ridge Cancer Care
    Roanoke, Virginia 24014, United States
  • Virginia Cancer Specialists - Winchester
    Winchester, Virginia 22601, United States
  • Northwest Medical Specialties
    Tacoma, Washington 98405, United States
  • Wenatchee Valley Hospital & Clinics
    Wenatchee, Washington 98801, United States
  • Instituto Damic
    Cordoba, X5003DCE, Argentina
  • Sanatorio Britanico: Hematologia
    Rosario, 2000, Argentina
  • Sanatorio Parque de Rosario
    Rosario, S2000DSV, Argentina
  • Cairns Base Hospital; Cancer Care Centre
    Cairns, Queensland 4870, Australia
  • Frankston Hospital; Oncology/Haematology
    Frankston, Victoria 3199, Australia
  • Monash Medical Centre; Haematology
    Melbourne, Victoria 3168, Australia
  • Fiona Stanley Hospital
    Murdoch, Western Australia 6150, Australia
  • Tiroler Landeskrankenanstalten Ges.M.B.H.; Innere Medizin Abt. Für Hämatologie & Onkologie
    Innsbruck, 6020, Austria
  • Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
    Salzburg, 5020, Austria
  • Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Hämatologie & Hämostaseologie
    Wien, 1090, Austria
  • Hospital Mae de Deus
    Porto Alegre, RS 90470-340, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Centro de Pesquisas Oncologicas - CEPON
    Florianopolis, SC 88034-000, Brazil
  • Instituto de Ensino e Pesquisa Sao Lucas - IEP
    Sao Paulo, SP 01236-030, Brazil
  • Hospital Santa Marcelina;Oncologia
    Sao Paulo, SP 08270-070, Brazil
  • Tom Baker Cancer Centre; Dept of Medicine
    Calgary, Alberta T2N 4N2, Canada
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • BCCA-Vancouver Cancer Centre
    Vancouver, British Columbia V5Z 4E6, Canada
  • Queen Elizabeth II Health Sciences Centre; Oncology
    Halifax, Nova Scotia B3H 2Y9, Canada
  • Ottawa General Hospital
    Ottawa, Ontario K1H 8L6, Canada
  • North York General Hospital
    Toronto, Ontario M2J 1V1, Canada
  • Humber River Hospital
    Toronto, Ontario M3M 0B2, Canada
  • University Health Network; Princess Margaret Hospital; Medical Oncology Dept
    Toronto, Ontario M5G 2M9, Canada
  • Hopital Maisonneuve- Rosemont; Oncology
    Montreal, Quebec H1T 2M4, Canada
  • Chum Hopital Notre Dame; Centre D'Oncologie
    Montreal, Quebec H2L 4M1, Canada
  • Mcgill University - Royal Victoria Hospital; Oncology
    Montreal, Quebec H3A 1A1, Canada
  • McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology
    Montreal, Quebec H3T 1E2, Canada
  • Hopital de L'Enfant-Jesus; Hematology
    Quebec City, Quebec G1J 1Z4, Canada
  • Centre de sante et de services sociaux Rimouski Neigette
    Rimouski, Quebec G5L 5T1, Canada
  • Saskatoon Cancer Centre; Uni of Saskatoon Campus
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Cancer Hospital Chinese Academy of Medical Sciences.
    Beijing, 100021, China
  • Peking University First Hospital
    Beijing, 100034, China
  • The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
    Beijing, 100071, China
  • Beijing Cancer Hospital
    Beijing, 100142, China
  • Beijing Hospital of Ministry of Health; Hematology
    Beijing, 100730, China
  • General Hospital of Chinese PLA; Department of Hematology
    Beijing, 100853, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • Hu Nan Provincial Cancer Hospital
    Changsha, 410006, China
  • Fujian Medical University Union Hospital
    Fujian, 350001, China
  • Fujian Cancer Hospital
    Fuzhou, 350014, China
  • Sun Yet-sen University Cancer Center
    Guangzhou, 510060, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • The First Affiliated Hospital of College of Medicine, Zhejiang University
    Hangzhou, 310003, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • The Second Affiliated Hospital to Nanchang University
    Nanchang, 330006, China
  • Jiangsu Cancer Hospital
    Nanjing, 210009, China
  • Jiangsu Province Hospital
    Nanjing, 210036, China
  • The First Affiliate Hospital of Guangxi Medical University
    Nanning, 530021, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, 200025, China
  • Fudan University Shanghai Cancer Center
    Shanghai, 200032, China
  • Changhai Hospital of Shanghai
    Shanghai, 200433, China
  • First Hospital of China Medical University
    Shenyang, 110001, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, 215004, China
  • First Affiliated Hospital of Soochow University
    Suzhou, 215006, China
  • Tianjin Cancer Hospital
    Tianjin, 300060, China
  • Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
    Wuhan, 430022, China
  • Union Hospital of Tongji Medical College, Dept. of Cancer Center; Cancer Center
    Wuhan, 430023, China
  • The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
    Xi'an, 710038, China
  • Fundacion Cardioinfantil
    Bogota, Colombia
  • Organizacion Sanitas Internacional
    Bogota, Colombia
  • FOSCAL
    Floridablanca, Colombia
  • Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika
    Brno, 625 00, Czechia
  • Fn Hr. Kralove; IV. Interni Hematologicka Klinika
    Hradec Kralove, 500 05, Czechia
  • Vseobecna Fakultni Nemocnice v Praze, I. Interni Klinika - Klinika Hematoonkologie VFN a 1. LF UK
    Praha 2, 128 08, Czechia

Showing the first 100 of 235 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Jemaa S, Paulson JN, Hutchings M, Kostakoglu L, Trotman J, Tracy S, de Crespigny A, Carano RAD, El-Galaly TC, Nielsen TG, Bengtsson T. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments. Cancer Imaging. 2022 Aug 12;22(1):39. doi: 10.1186/s40644-022-00476-0. PubMed 35962459 ↗
  • Nowicka M, Hilton LK, Ashton-Key M, Hargreaves CE, Lee C, Foxall R, Carter MJ, Beers SA, Potter KN, Bolen CR, Klein C, Knapp A, Mir F, Rose-Zerilli M, Burton C, Klapper W, Scott DW, Sehn LH, Vitolo U, Martelli M, Trneny M, Rushton CK, Slack GW, Farinha P, Strefford JC, Oestergaard MZ, Morin RD, Cragg MS. Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. Blood Adv. 2021 Aug 10;5(15):2945-2957. doi: 10.1182/bloodadvances.2021004770. PubMed 34323958 ↗
  • Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trneny M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Single-nucleotide Fcgamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985. PubMed 34323957 ↗
  • Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trneny M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021 Mar 9;5(5):1283-1290. doi: 10.1182/bloodadvances.2020002690. PubMed 33651099 ↗
  • Bolen CR, Klanova M, Trneny M, Sehn LH, He J, Tong J, Paulson JN, Kim E, Vitolo U, Di Rocco A, Fingerle-Rowson G, Nielsen T, Lenz G, Oestergaard MZ. Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. Haematologica. 2020 Sep 1;105(9):2298-2307. doi: 10.3324/haematol.2019.227892. PubMed 33054054 ↗
  • Sehn LH, Martelli M, Trneny M, Liu W, Bolen CR, Knapp A, Sahin D, Sellam G, Vitolo U. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol. 2020 Jun 6;13(1):71. doi: 10.1186/s13045-020-00900-7. PubMed 32505213 ↗
  • Klanova M, Oestergaard MZ, Trneny M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3. PubMed 31053601 ↗
  • McCord R, Bolen CR, Koeppen H, Kadel EE 3rd, Oestergaard MZ, Nielsen T, Sehn LH, Venstrom JM. PD-L1 and tumor-associated macrophages in de novo DLBCL. Blood Adv. 2019 Feb 26;3(4):531-540. doi: 10.1182/bloodadvances.2018020602. PubMed 30770362 ↗
  • Klanova M, Sehn LH, Bence-Bruckler I, Cavallo F, Jin J, Martelli M, Stewart D, Vitolo U, Zaja F, Zhang Q, Mattiello F, Sellam G, Punnoose EA, Szafer-Glusman E, Bolen CR, Oestergaard MZ, Fingerle-Rowson GR, Nielsen T, Trneny M. Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. Blood. 2019 Feb 28;133(9):919-926. doi: 10.1182/blood-2018-07-862862. Epub 2019 Jan 7. PubMed 30617197 ↗
  • Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019 Jan 10;133(2):137-146. doi: 10.1182/blood-2018-04-848044. Epub 2018 Oct 19. PubMed 30341058 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2011 to primary completion in Apr 2016, 57 months.

Results were first posted in Aug 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2011
First posted
Feb 1, 2011
StartActual
Jul 26, 2011
Primary completionActual
Apr 29, 2016
CompletionActual
Jan 31, 2018
Results first posted
Aug 17, 2017
Last update
Apr 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01287741
Lead sponsor
Hoffmann-La Roche
Collaborators
Fondazione Italiana Linfomi - ETS
Responsible party
Sponsor
First posted
Feb 1, 2011
Start date
Jul 26, 2011
Primary completion
Apr 29, 2016
Completion
Jan 31, 2018
Results posted
Aug 17, 2017
Last update
Apr 12, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Obinutuzumab

Start the discussion